RPE65: Retinoid isomerohydrolase
Critical isomerohydrolase in the retinoid cycle involved in regeneration of 11-cis-retinal, the chromophore of rod and cone opsins.
- Drugs that act on it: 2
- Approved: 1
- In phases 1 to 3: 1
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on RPE65, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
- Other 1
| Voretigene neparvovec | Approved | Spark Therapeutics | Gene | Exogenous geneRetinoid isomerohydrolase exogenous gene | 4 |
| Emixustat | Phase 3 | Kubota Vision Inc. | Small molecule | InhibitorRetinoid isomerohydrolase inhibitor | 0 |
| Monitoring and Early Detection of Treatable Inherited RETinal Disease in Children and Adolescents | Voretigene neparvovec | — | Recruiting | University College, London | Oct 28, 2026 |
| Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2) | Voretigene neparvovec | — | Active, not recruiting | Genentech, Inc. | Jul 27, 2018 |
| Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2 | Voretigene neparvovec | Phase 1 / Phase 2 | Active, not recruiting | Spark Therapeutics, Inc. | Sep 24, 2010 |
| Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis | Voretigene neparvovec | Phase 3 | Active, not recruiting | Spark Therapeutics, Inc. | Oct 22, 2009 |
- Retinitis pigmentosa0.84
- Leber congenital amaurosis 20.82
- Leber congenital amaurosis0.77
- Inherited retinal dystrophy0.69
- RPE65-related recessive retinopathy0.68
- Retinitis pigmentosa 87 with choroidal involvement0.65
- Hereditary disease0.52
- Autosomal recessive retinitis pigmentosa0.51
- Stargardt disease0.45
- Retinal disorder0.42
- Abnormality of the eye0.41
- Severe early-childhood-onset retinal dystrophy0.39
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3831182, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q16518, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets